New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

Findings seen over three months in men with low-grade prostate cancer, hypogonadism treated with radical prostatectomy.

Procept BioRobotics anticipates sharing the primary endpoint results from WATER IV in 2027.

Up to 72% of patients with prostate cancer who undergo radical prostatectomy experience urinary incontinence in the first 3 months after surgery. Up to 72% of patients experience urinary incontinence ...

Among men with high-risk localized prostate cancer, those receiving neoadjuvant apalutamide combination therapy had improved potency recovery by 12 months and reduced rates of positive margins ...

Procept BioRobotics (Nasdaq:PRCT) announced that it received FDA investigational device exemption (IDE) for a second ...